Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia

American Journal of Health-System Pharmacy

Volumn 67, Issue 9, 2010, Pages 713-723

  Elefante, Anjana ^a   Czuczman, Myron S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Antineoplastic agents; Bendamustine hydrochloride; Combined therapy; Dosage; Drug administration; Leukemia; Lymphoma; Mechanism of action; Toxicity

Indexed keywords

ALLOPURINOL; BENDAMUSTINE; CEPHALOSPORIN DERIVATIVE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREDNISONE; QUINOLONE DERIVATIVE; RITUXIMAB; SULFONAMIDE; TETRACYCLINE DERIVATIVE; VINCRISTINE; VORICONAZOLE; ANTINEOPLASTIC AGENT; CHLORMETHINE DERIVATIVE;

ANAPHYLAXIS; ANEMIA; ANOREXIA; APOPTOSIS; BONE MARROW SUPPRESSION; CANDIDIASIS; CELL CYCLE ARREST; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; COUGHING; CYANOSIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DIVERTICULITIS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HERPES ZOSTER; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; HYPOTENSION; INFECTION; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE REACTION; LEUKOPENIA; LUNG CANCER; MANTLE CELL LYMPHOMA; MITOSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NEUTROPENIA; NONHODGKIN LYMPHOMA; OROPHARYNX CANDIDIASIS; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SECOND CANCER; SEPSIS; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STEVENS JOHNSON SYNDROME; TACHYCARDIA; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; UROSEPSIS;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; NITROGEN MUSTARD COMPOUNDS;

EID: 77955062266     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp090328     Document Type: Review

References (45)

1. United States Food and Drug Administration. Approval letter NDA 22-249. www.accessdata.fda.gov/drugsatfda- docs/appletter/2008/022249s000ltr.pdf (accessed 2010 Mar 4).
2. United States Food and Drug Administration. Approval letter NDA 22-303. www.accessdata.fda.gov/drugsatfda- docs/appletter/2008/022303s000ltr.pdf (accessed 2010 Mar 4).
3. Anger G, Hesse P, Baufield H. Treatment of multiple myeloma with a new cytostatic agent: gamma-1-methyl-5-bis-(beta-chlorethyl)- amino-benzimidazolyl- (2)- butyric acid hydrochloride. Dtsch Med Wochenschr. 1969; 94:2495-500.
4. Knauf WU, Lissichkov T, Aldaoud A et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009; 27:4378-84.
5. Friedberg JW, Cohen P, Chen L et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008; 26:204-10.
6. Kahl BS, Bartlett NL, Leonard JP et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin's lymphoma: results from a multicenter study. Cancer. 2010; 116:106-14.
7. ClinicalTrials.gov. Bendamustine studies. www.clinicaltrials.gov/ct2/ results?term=bendamustine (accessed 2010 Feb 1).
8. Leoni LM, Bailey B, Reifert J et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008; 14:309-17.
9. Strumberg D, Harstrick A, Doll K et al. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs. 1996; 7:415-21.
10. Schwanen C, Hecker T, Hubinger G et al. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia. 2002; 16:2096-105.
11. Konstantinov SM, Kostovski A, Topashka- Ancheva M et al. Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines. J Cancer Res Clin Oncol. 2002; 128:271-8. (Pubitemid 34591585)
12. Chow KU, Boehrer S, Geduldig K et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica. 2001; 86:485-93.
13. Chow KU, Sommerlad WD, Boehrer S et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica. 2002; 87:33-43.
14. Rummel MJ, Chow KU, Hoelzer D et al. In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin Oncol. 2002; 29:12-4.
15. Owen JS, Melhem M, D'Andrea D et al. Population pharmacokinetics of bendamustine and metabolites in patients with indolent non-Hodgkin lymphoma. Pharmacol Ther. 2008; 83(suppl 1):S54. Abstract.
16. Teichert J, Baumann F, Chao Q et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol. 2007; 59:759-70.
17. Treanda (bendamustine hydrochloride) for injection, for intravenous infusion, package insert. Frazer, PA: Cephalon, Inc.; 2009 Apr.
18. American Cancer Society. Cancer facts and figures 2009. www.cancer.org/ downlo ads/STT/500809web.pdf (accessed 2010 Feb 1).
19. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Non-Hodgkin's lymphomas. V.1.2009. www.nccn.org/professionals/ physician-gls/PDF.nhl.pdf (accessed 18 Mar 2010).
20. Hainsworth JD, Litchy S, Shaffer DW et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin's lymphoma - a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005; 23:1088-95. (Pubitemid 46202263)
21. Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs. 2001; 12:725-9.
22. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol. 2002; 128:603-9.
23. Robinson KS, Williams ME, van der Jagt RH et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008; 26:4473-9.
24. Herold M, Schulze A, Niederwieser D et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol. 2006; 132:105-12.
25. Rummel MJ, von Gruenhagen U, Niederle N et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line- treatment of patients with follicular, indolent and mantle cell lymphomas: results of a randomized phase III study of the study group indolent lymphomas (StiL). Blood. 2008; 112:2596. Abstract.
26. Lissitchkov T, Arnaudov G, Peytchev D et al. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol. 2006; 132:99-104.
27. Bergmann MA, Goebeler ME, Herold M et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica. 2005; 90:1357-64.
28. Niederle N, Balleisen L, Heit W et al. Bendamustine vs fludarabine as second-line treatment for patients with chronic lymphocytic leukemia - first interim results of a randomized study. Ann Oncol. 2008; 19(suppl 4):abstract 379.
29. Fischer K, Stilgenbauer S, Schweighofer CD et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL study group (GCLLSG). Blood. 2008; 112:300. Abstract.
30. ClinicalTrials.gov. Fludarabine, cyclophosphamide, and rituximab or bendamustine and rituximab in treating patients with previously untreated B-cell chronic lym-phocytic leukemia. www.clinicaltrials.gov/ct2/show/ NCT00769522 (accessed 2010 Feb 1).
31. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Multiple myeloma. V.1.2009. www.nccn.org/professionals/physician- gls/PDF/myeloma.pdf (accessed 18 Mar 2010).
32. Pönisch W, Mitrou PS, Merkle K et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone - a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006; 132:205-12. (Pubitemid 43144255)
33. ClinicalTrials.gov. Bendamustine HCl in relapsed and primary refractory Hodgkin lymphoma. www.clinicaltrials.gov/ct2/ show/NCT00705250 (accessed 2010 Feb 1).
34. Reichmann U, Bokemeyer C, Wallwiener D et al. Salvage chemotherapy for meta-static breast cancer: results of a phase II study with bendamustine. Ann Oncol. 2007; 18:1981-4.
35. Hoffken K, Merkle K, Schonfelder M et al. Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. J Cancer Res Clin Oncol. 1998; 124:627-32.
36. Eichbaum MH, Schuetz F, Khbeis T et al. Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study. Anticancer Drugs. 2007; 18:963-8.
37. Koster W, Heider A, Niederle N et al. Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer. J Thorac Oncol. 2007; 2:312-6.
38. Schmittel A, Knodler M, Hortig P et al. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer. 2007; 55:109-13.
39. Hartmann JT, Mayer F, Schleicher J et al. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). Cancer. 2007; 110:861-6. (Pubitemid 47257665)
40. Kollmannsberger C, Gerl A, Schleucher N et al. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer. Anticancer Drugs. 2000; 11:535-9.
41. Von Minckwitz G, Chernozemsky I, Sirakova L et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs. 2005; 16:871-7.
42. Rummel MJ, Al-Batran SE, Kim SZ et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005; 23:3383-9.
43. Coiffier B, Altman A, Pui CH et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008; 26:2767-78.
44. Cheson BD. Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2009; 7:263-71.
45. Smith LH. Toxic epidermal necrolysis. Clin J Oncol Nurs. 2007; 11:333-6.